Successfully treated sulphasalazine-induced fulminant hepatic failure, thrombocytopenia and erythroid hypoplasia with intravenous immunoglobulin.
We report the simultaneous development of fulminant hepatic failure, thrombocytopenia and erythroid hypoplasia in a child treated with sulphasalazine. A 12-year-old girl with juvenile rheumatoid arthritis developed fulminant hepatic failure, thrombocytopenia and erythroid hypoplasia, which was confirmed by liver histology and bone marrow examination, 2 weeks after initiation of sulphasalazine therapy. The patient recovered after administration of high doses of intravenous immunoglobulin. This is the first reported case of the concurrent development of these complications associated with sulphasalazine hypersensitivity. The use of intravenous immunoglobulin may have helped in the treatment of this rare adverse effect of sulphasalazine.
Huang
J L
JL
Department of Pediatrics, Chang Gung Children's Hospital and Chang Gung University, Taoyuan, Taiwan.
Hung
I J
IJ
Chen
L C
LC
Lee
W Y
WY
Hsueh
C
C
Hsieh
K H
KH
D018501:Antirheumatic Agents / Q000009:adverse effects*; D001171:Arthritis, Juvenile / Q000188:drug therapy; D002648:Child; D005260:Female; D005500:Follow-Up Studies; D006501:Hepatic Encephalopathy / Q000139:chemically induced / Q000150:complications / Q000628:therapy*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D012010:Red-Cell Aplasia, Pure / Q000139:chemically induced / Q000150:complications / Q000628:therapy*; D012460:Sulfasalazine / Q000009:adverse effects*; D013921:Thrombocytopenia / Q000139:chemically induced / Q000150:complications / Q000628:therapy*
D018501:Antirheumatic Agents; D016756:Immunoglobulins, Intravenous; D012460:Sulfasalazine